Aerovate Therapeutics

Aerovate is a biotechnology company dedicated to developing drugs that can significantly improve the lives of patients with rare cardiopulmonary diseases. Aerovate's lead program is a potential disease-modifying drug for people with pulmonary arterial hypertension (PAH). AV-101 is a proprietary inhaled dry powder formulation of imatinib that delivers the drug directly to the diseased lung tissue while reducing systemic adverse effects.